डॉक्टर से बिना सलाह न करें इन दवाओं का सेवन, हो सकते है ये बड़े नुकसा
https://thehealthmaster.com/?p=36419
Thursday, March 31, 2022
Side effects: डॉक्टर से बिना सलाह न करें इन दवाओं का सेवन, हो सकते है ये बड़े नुकसान: very important
https://thehealthmaster.com/?p=36419
Side effects: डॉक्टर से बिना सलाह न करें इन दवाओं का सेवन, हो सकते है ये बड़े नुकसान: very important
डॉक्टर से बिना सलाह न करें इन दवाओं का सेवन, हो सकते है ये बड़े नुकसा
https://thehealthmaster.com/?p=36419
Wednesday, March 30, 2022
The National Pharmaceutical Pricing Authority (NPPA) has further extended the revised ceiling price of two strengths of heparin injection, liquid medical oxygen (LMO) and oxygen inhalation for another six months in order to ensure continuous availability of the drug during C-19 pandemic.
The revised ceiling prices of heparin injection 5000IU/ml and 1000 IU/ml extended for the fourth time, for a period of six months till September 30, 2022.
The committee constituted to monitor export/import trends of APIs, formulations and medical devices needed for C-19 in a letter on March 15, 2022 recommended that the authority may continue with the increased ceiling price for the injection for another six months to ensure continuous availability of this essential drug in the current pandemic situation.
Click for more articles on NPPA
It was first revised upwards by the Authority through an order on June 30, 2020, based on applications from several companies having major market share.
The companies requested for an upward revision of ceiling prices of the drug citing reasons that the cost of active pharmaceutical ingredients (APIs) which constitute a major portion of the input cost and mainly imported from China, has risen to a considerable extent making the companies entirely unviable to continue manufacture and formulations.
The companies also contended that over the years the regulated price have decreased whereas there is consistent increase in the imported price of APIs thereby making it commercially unviable for the drug manufacturers to manufacture heparin injections.
The ministry of health and family welfare (MoH&FW) has included heparin 5000IU/ml as an essential medicine for treatment of C-19 patients. There were reports of shortage of the injection during the time of pandemic.
In an earlier report, the Committee has informed that there has been considerable increase in price of API heparin when compared to the base year of September, 2018. The committee recommended short term upward price revision of heparin injection.
Click for more articles on DPCO 2013
The NPPA, based on these recommendations, on June 30, 2020, revised the ceiling prices upwards by giving a one time increase of 50 per cent from the existing ceiling price to be applicable up to December 31, 2020.
The ceiling price excluding GST was thus fixed as Rs. 24.39 for heparin injection 1000 IU/ml for a unit of 1 ml and Rs 60.54 for heparin injection 5000 IU/ml for 1 ml.
The Authority has also extended the period for price cap on liquid medical oxygen (LMO) and oxygen inhalation (medicinal gas) from March 31, 2022 to three more months till June 30, 2022, in public interest.
This is for the fourth time the drug price watchdog has extended the revised price of these products in the backdrop of C-19 pandemic and increased demand.
The Department for Promotion of Industry and Internal Trade (DPIIT), ministry of commerce and industry, through an Office Memorandum on March 24, 2022, recommended that the prices of the LMO and medicinal gas may further be extended to another three months beyond March 31, after which the issue may be reviewed by the Department again.
NPPA, in view of continuing extraordinary circumstances due to the C-19 pandemic, decided that the revised price of LMO and medicinal gas fixed for the first time through the order on September 25, 2020, be further extended up to June 30, 2022, or until further order, whichever is earlier, in public interest.
The Authority, on September, 2020, observed that the demand for medical oxygen has gone up almost four times, from 750 MT per day to around 2,800 MT per day, due to C-19 pandemic.
During the pandemic, around 50 percent of the total liquid oxygen production is being used for medical purposes in comparison to around 15 per cent usage during the pre-C-19 period.
Medicinal gas is a scheduled formulation under the amended Schedule I of Drugs (Prices Control) Order , 2013, and NPPA had notified its ceiling price as Rs. 17.49 per cubic meter excluding goods and service tax (GST) from March 25, 2020.
The union ministry of health and family welfare has delegated powers to NPPA to take steps to immediately regulate the availability and pricing of LMO and medical oxygen cylinders.
The Authority, through the order, during the time fixed the ex-factory maximum price of LMO at Rs. 15.22 per cubic meter, excluding GST and Rs. 25.71 for medicinal gas per cubic meter in cylinder, inclusive of inward transportation cost incurred for LMO up to filler.
The manufacturers not complying with the price cap, shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955, said the order.
Must read
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
Latest Notifications: EC Act (Essential Commodities Act)
FAQs – On DPCO: Drugs (Prices Control) Order, 2013
Local manufacturing of 35 APIs started after PLI scheme
Telangana to fill posts of 18 Drug Inspectors, 442 Pharmacists and 15 junior Analysts
Drug recall: Orphenadrine Citrate 100 mg Extended Release Tablets recalled due…
Telangana Minister pitches Hyderabad as Pharma Hub
NPPA updated price lists: Download
NPPA allows price hike of Essential Medicines by more than 10 percent
WHO establishes Global Centre for Traditional Medicine in India
Maharashtra FDA to get 15 new Asstt. Commissioners to combat impending…
USFDA probe of Abbott facility finds quality control issues
Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/03/30/nppa-extends-price-revision-of-heparin-injection-lmo-and-oxygen-inhalation/
The National Pharmaceutical Pricing Authority (NPPA) has further extended the revised ceiling price of two strengths of heparin injection, liquid medical oxygen (LMO) and oxygen inhalation for another six months in order to ensure continuous availability of the drug during Covid-19 pandemic.
The revised ceiling prices of heparin injection 5000IU/ml and 1000 IU/ml extended for the fourth time, for a period of six months till September 30, 2022. The committee constituted to monitor export/import trends of APIs, formulations and medical devices needed for Covid-19 in a letter on March 15, 2022 recommended that the authority may continue with the increased ceiling price for the injection for another six months to ensure continuous availability of this essential drug in the current pandemic situation.
It was first revised upwards by the Authority through an order on June 30, 2020, based on applications from several companies having major market share.
The companies requested for an upward revision of ceiling prices of the drug citing reasons that the cost of active pharmaceutical ingredients (APIs) which constitute a major portion of the input cost and mainly imported from China, has risen to a considerable extent making the companies entirely unviable to continue manufacture and formulations.
The companies also contended that over the years the regulated price have decreased whereas there is consistent increase in the imported price of APIs thereby making it commercially unviable for the drug manufacturers to manufacture heparin injections.
The ministry of health and family welfare (MoH&FW) has included heparin 5000IU/ml as an essential medicine for treatment of Covid-19 patients. There were reports of shortage of the injection during the time of pandemic.
In an earlier report, the Committee has informed that there has been considerable increase in price of API heparin when compared to the base year of September, 2018. The committee recommended short term upward price revision of heparin injection.
The NPPA, based on these recommendations, on June 30, 2020, revised the ceiling prices upwards by giving a one time increase of 50 per cent from the existing ceiling price to be applicable up to December 31, 2020. The ceiling price excluding GST was thus fixed as Rs. 24.39 for heparin injection 1000 IU/ml for a unit of 1 ml and Rs 60.54 for heparin injection 5000 IU/ml for 1 ml.
The Authority has also extended the period for price cap on liquid medical oxygen (LMO) and oxygen inhalation (medicinal gas) from March 31, 2022 to three more months till June 30, 2022, in public interest. This is for the fourth time the drug price watchdog has extended the revised price of these products in the backdrop of Covid-19 pandemic and increased demand.
The Department for Promotion of Industry and Internal Trade (DPIIT), ministry of commerce and industry, through an Office Memorandum on March 24, 2022, recommended that the prices of the LMO and medicinal gas may further be extended to another three months beyond March 31, after which the issue may be reviewed by the Department again.
NPPA, in view of continuing extraordinary circumstances due to the Covid pandemic, decided that the revised price of LMO and medicinal gas fixed for the first time through the order on September 25, 2020, be further extended up to June 30, 2022, or until further order, whichever is earlier, in public interest.
The Authority, on September, 2020, observed that the demand for medical oxygen has gone up almost four times, from 750 MT per day to around 2,800 MT per day, due to Covid-19 pandemic. During the pandemic, around 50 percent of the total liquid oxygen production is being used for medical purposes in comparison to around 15 per cent usage during the pre-Covid period.
Medicinal gas is a scheduled formulation under the amended Schedule I of Drugs (Prices Control) Order , 2013, and NPPA had notified its ceiling price as Rs. 17.49 per cubic meter excluding goods and service tax (GST) from March 25, 2020. The union ministry of health and family welfare has delegated powers to NPPA to take steps to immediately regulate the availability and pricing of LMO and medical oxygen cylinders.
The Authority, through the order, during the time fixed the ex-factory maximum price of LMO at Rs. 15.22 per cubic meter, excluding GST and Rs. 25.71 for medicinal gas per cubic meter in cylinder, inclusive of inward transportation cost incurred for LMO up to filler. The manufacturers not complying with the price cap, shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955, said the order.
Local manufacturing of 35 APIs started after PLI scheme
Telangana to fill posts of 18 Drug Inspectors, 442 Pharmacists and 15 junior Analysts
Drug recall: Orphenadrine Citrate 100 mg Extended Release Tablets recalled due…
Telangana Minister pitches Hyderabad as Pharma Hub
NPPA updated price lists: Download
NPPA allows price hike of Essential Medicines by more than 10 percent
WHO establishes Global Centre for Traditional Medicine in India
Maharashtra FDA to get 15 new Asstt. Commissioners to combat impending…
USFDA probe of Abbott facility finds quality control issues
Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/03/30/nppa-extends-price-revision-of-heparin-injection-lmo-and-oxygen-inhalation/
Tuesday, March 29, 2022
Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a voluntary recall of 13 lots (listed below) of oral Orphenadrine Citrate 100 mg Extended Release (ER) Tablets to the consumer level.
The presence of a nitrosamine (N-methyl-N-nitroso-2- ethanamine (NMOA or Nitroso-Orphenadrine)) impurity, which has the potential to be above the U.S. Food and Drug Administration (USFDA)’s Acceptable Daily Intake (ADI) limit of 26.5 ng/day, was detected in the lots during recent testing.
Click for more drugs recall
These 13 lots of Orphenadrine Citrate ER Tablets were shipped to customers from August 2019 to April 2021.
Nitrosamines are substances with carcinogenic potency (substances that could cause cancer) when present above the allowable exposure limits.
While the use of product belonging to the recalled lots may represent a risk to patients, to date, Sandoz has not received any reports of adverse events related to the presence of a nitrosamine impurity in the lot.
Orphenadrine Citrate ER Tablets are used as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. The product is packaged in 100-count and 1000-count bottles and was distributed nationwide in the USA to wholesalers and distributors.
Click for more articles on USFDA
Product NameNDC NumberLot NumberExpiration DateDate of ManufactureOrphenadrine Citrate ER Tablets0185-0022-01JX641105/20225/24/2019Orphenadrine Citrate ER Tablets0185-0022-01JX641305/20225/24/2019Orphenadrine Citrate ER Tablets0185-0022-01KC072308/20228/21/2019Orphenadrine Citrate ER Tablets0185-0022-01KC330308/20228/21/2019Orphenadrine Citrate ER Tablets0185-0022-01KE434811/202211/6/2019Orphenadrine Citrate ER Tablets0185-0022-01KE716911/202211/6/2019Orphenadrine Citrate ER Tablets0185-0022-01KE434911/202211/6/2019Orphenadrine Citrate ER Tablets0185-0022-01KL319903/20233/3/2020Orphenadrine Citrate ER Tablets0185-0022-01KM007203/20233/3/2020Orphenadrine Citrate ER Tablets0185-0022-10KS3939+03/20233/3/2020Orphenadrine Citrate ER Tablets0185-0022-01LA770410/202310/6/2020Orphenadrine Citrate ER Tablets0185-0022-01LA770310/202310/6/2020Orphenadrine Citrate ER Tablets0185-0022-01LA924311/202311/18/2020
+ 1,000-count bottle
This recall of Orphenadrine Citrate ER Tablets is specific to the lots listed above and does not apply to any other strengths of Sandoz Orphenadrine Citrate ER Tablets nor to other lot numbers of the product. Any product returned that is not associated with this recall will be destroyed, and no credit will be issued.
Sandoz is notifying its wholesalers and distributors by mail and is arranging for the return of all recalled product. Wholesalers and distributors that have Orphenadrine Citrate ER Tablets subject to this recall should immediately stop distribution of the recalled product and quarantine and return all recalled product in their inventory.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
NPPA updated price lists: Download
NPPA allows price hike of Essential Medicines by more than 10 percent
WHO establishes Global Centre for Traditional Medicine in India
Maharashtra FDA to get 15 new Asstt. Commissioners to combat impending…
USFDA probe of Abbott facility finds quality control issues
DCGI calls on stakeholders to initiate Clinical Trials early
USFDA gives nod to Lupin for Sildenafil for oral suspension
NPPA’s expert panel recommends retail price for FDCs of anti-diabetic linagliptin
DCGI gives nod to Phase-3 Clinical Trial of Covovax Vaccine
Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/03/28/drug-recall-orphenadrine-citrate-100-mg-extended-release-tablets-recalled-due-to-this-reason/
NPPA updated price lists: Download
NPPA updated price lists: Download
https://thehealthmaster.com/2022/03/27/nppa-updated-price-lists-download/
Healthy Drinks: सोडा से बेहतर हैं ये 5 तरह के हेल्दी ड्रिंक्स, गर्मी में देंगे ताजगी और एनर्जी
सोडा से बेहतर हैं ये 5 तरह के हेल्दी ड्रिंक्स, गर्मी में देंगे ताजगी और एनर्जी
https://thehealthmaster.com/?p=36332
Monday, March 28, 2022
HYDERABAD: Telangana industries & IT minister KT Rama Rao, who is on a week-long US trip hard-selling Telangana as an investment destination, met top honchos of the world’s top three pharma players — Pfizer, Johnson & Johnson and GlaxoSmithKline — in New York.
Not only did KTR pitch Telangana’s life sciences sector, especially the Hyderabad cluster, he also sought their suggestions on boosting the city’s life sciences innovation quotient and invited them for the 20th edition of BioAsia that is scheduled to be held in February 2023 in Hyderabad.
Click for more articles on Telangana
In a bid to get a sense of the $42 billion turnover Pfizer’s strategy and plans for India’s healthcare and pharma sector, KTR met its chairman & chief executive officer Albert Bourla and also showcased Telangana’s vibrant life sciences ecosystem that accounts for a chunk of the global vaccine supply.
The Telangana delegation, which also included industries department principal secretary Jayesh Ranjan and life sciences director Shakthi M Nagappan, also met Pfizer’s EVP & chief global supply officer Mike McDermott as well as its SVP & chief scientific officer Dr Uwe Schoenbeck.
Click for more articles on Pharma Hub
At the office of the $82 billion turnover J&J, KTR held deliberations with its EVP of pharmaceutical R&D Dr Mathai Mammen.
The minister also met Agam Upadhyay, SVP & chief technology officer, GlaxoSmithKline (GSK), to acquaint him with Hyderabad’s technological and digital innovation capabilities.
NPPA updated price lists: Download
NPPA allows price hike of Essential Medicines by more than 10 percent
WHO establishes Global Centre for Traditional Medicine in India
Maharashtra FDA to get 15 new Asstt. Commissioners to combat impending…
USFDA probe of Abbott facility finds quality control issues
DCGI calls on stakeholders to initiate Clinical Trials early
USFDA gives nod to Lupin for Sildenafil for oral suspension
NPPA’s expert panel recommends retail price for FDCs of anti-diabetic linagliptin
DCGI gives nod to Phase-3 Clinical Trial of Covovax Vaccine
Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/03/28/telangana-minister-pitches-hyderabad-as-pharma-hub/
Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a voluntary recall of 13 lots (listed below) of oral Orphenadrine Citrate 100 mg Extended Release (ER) Tablets to the consumer level.
The presence of a nitrosamine (N-methyl-N-nitroso-2-ethanamine (NMOA or Nitroso-Orphenadrine)) impurity, which has the potential to be above the U.S. Food and Drug Administration (USFDA)’s Acceptable Daily Intake (ADI) limit of 26.5 ng/day, was detected in the lots during recent testing.
Click for more drugs recall
These 13 lots of Orphenadrine Citrate ER Tablets were shipped to customers from August 2019 to April 2021.
Nitrosamines are substances with carcinogenic potency (substances that could cause cancer) when present above the allowable exposure limits.
While the use of product belonging to the recalled lots may represent a risk to patients, to date, Sandoz has not received any reports of adverse events related to the presence of a nitrosamine impurity in the lot.
Orphenadrine Citrate ER Tablets are used as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. The product is packaged in 100-count and 1000-count bottles and was distributed nationwide in the USA to wholesalers and distributors.
Click for more articles on USFDA
Product NameNDC NumberLot NumberExpiration DateDate of ManufactureOrphenadrine Citrate ER Tablets0185-0022-01JX641105/20225/24/2019Orphenadrine Citrate ER Tablets0185-0022-01JX641305/20225/24/2019Orphenadrine Citrate ER Tablets0185-0022-01KC072308/20228/21/2019Orphenadrine Citrate ER Tablets0185-0022-01KC330308/20228/21/2019Orphenadrine Citrate ER Tablets0185-0022-01KE434811/202211/6/2019Orphenadrine Citrate ER Tablets0185-0022-01KE716911/202211/6/2019Orphenadrine Citrate ER Tablets0185-0022-01KE434911/202211/6/2019Orphenadrine Citrate ER Tablets0185-0022-01KL319903/20233/3/2020Orphenadrine Citrate ER Tablets0185-0022-01KM007203/20233/3/2020Orphenadrine Citrate ER Tablets0185-0022-10KS3939+03/20233/3/2020Orphenadrine Citrate ER Tablets0185-0022-01LA770410/202310/6/2020Orphenadrine Citrate ER Tablets0185-0022-01LA770310/202310/6/2020Orphenadrine Citrate ER Tablets0185-0022-01LA924311/202311/18/2020
+ 1,000-count bottle
This recall of Orphenadrine Citrate ER Tablets is specific to the lots listed above and does not apply to any other strengths of Sandoz Orphenadrine Citrate ER Tablets nor to other lot numbers of the product. Any product returned that is not associated with this recall will be destroyed, and no credit will be issued.
Sandoz is notifying its wholesalers and distributors by mail and is arranging for the return of all recalled product. Wholesalers and distributors that have Orphenadrine Citrate ER Tablets subject to this recall should immediately stop distribution of the recalled product and quarantine and return all recalled product in their inventory.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
NPPA updated price lists: Download
NPPA allows price hike of Essential Medicines by more than 10 percent
WHO establishes Global Centre for Traditional Medicine in India
Maharashtra FDA to get 15 new Asstt. Commissioners to combat impending…
USFDA probe of Abbott facility finds quality control issues
DCGI calls on stakeholders to initiate Clinical Trials early
USFDA gives nod to Lupin for Sildenafil for oral suspension
NPPA’s expert panel recommends retail price for FDCs of anti-diabetic linagliptin
DCGI gives nod to Phase-3 Clinical Trial of Covovax Vaccine
Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/03/28/drug-recall-orphenadrine-citrate-100-mg-extended-release-tablets-recalled-due-to-this-reason/
NPPA updated price lists: Download
NPPA updated price lists: Download
https://thehealthmaster.com/2022/03/27/nppa-updated-price-lists-download/
UTI: यूरिनरी ट्रैक्ट इंफेक्शन में नजर आते हैं ये लक्षण: ऐसे करें Prevention
UTI: यूरिनरी ट्रैक्ट इंफेक्शन में नजर आते हैं ये लक्षण: ऐसे करें Prevention
https://thehealthmaster.com/?p=36313
Healthy Drinks: सोडा से बेहतर हैं ये 5 तरह के हेल्दी ड्रिंक्स, गर्मी में देंगे ताजगी और एनर्जी
सोडा से बेहतर हैं ये 5 तरह के हेल्दी ड्रिंक्स, गर्मी में देंगे ताजगी और एनर्जी
https://thehealthmaster.com/?p=36332
Sunday, March 27, 2022
The Union Public Service Commission commonly abbreviated as UPSC, is India's premier central recruiting agency. It is responsible for appointments to and examinations for All India services and group A & group B of Central services. While Department of Personnel and Training is the central personnel agency in India.
The agency's charter is granted by Part XIV of the Constitution of India, titled as Services Under the Union and the States. The commission is mandated by the Constitution for appointments to the services of the Union and All India Services.
It is also required to be consulted by the Government in matters relating to the appointment, transfer, promotion and disciplinary matters. The commission reports directly to the President and can advise the Government through him.
Although, such advice is not binding on the Government. Being a constitutional authority, UPSC is amongst the few institutions which function with both autonomy and freedom, along with the country’s higher judiciary and lately the Election Commission.
Post : Scientist ‘B’ (Toxicology)
No of Post : 01
Vacancy Number : 22030503212Ministry/Administration : Ministry of Home AffairsDepartment/Office : Directorate of Forensic Science ServicesOrganisation : Central Forensic Science Laboratory
Pay Scale : Pay Level-10 (56100-177500) of pay matrix under CCS (RP) Rules, 2016. (Total emoluments excluding T.A. & HRA at the time of initial appointment will be Rs.56100/- plus DA as applicable per month)Age : Not exceeding 35 years as on normal closing date. Relaxable for regularly appointed Central/UTs Govt. Servants upto 5 years’ as per instructions/orders issued by the Govt. of India from time to time. For age concession applicable to some others categories of applicants, please see relevant paras of the, ‘Instructions and Additional Information to Candidates for Recruitments by Selection.
Essential Qualification : A. Educational - (I) Masters Degree in Chemistry/ AIC by examination/ Biochemistry/ Pharmacology/ Pharmacy/ Forensic Science. and(II) Bachelor of Science Degree with Chemistry as one of the subjects from a recognized University or Institute.
NOTE- Qualifications are relaxable at the discretion of the UPSC for reasons to be recorded in writing in case of candidates otherwise well qualified.
B. Experience- Three(03) years experience of analytical methods and research therein in the field of Toxicology in any Central Government or State Government organization or recognized research institute or Forensic Science Laboratory under the Central or State Government.
Desirable Qualification : Experience of working in a Forensic Science Laboratory.
Duty(ies) : Crime Scene Management, Crime Case Examination, bestow expert testimony/de’facto in the courts of law on subject matter under the provision of Cr.P.C. and Indian Evidence Act/ Information Technology Act, R&D activities on Forensic Activities and imparting training in their respective field of forensic specialization to the trainees from different investigating agencies/forensic science labs and other organizations.
Probation : 01 (One) year
Other Details :General Central Service Group-A (Gazetted) Non-Ministerial. The post is permanent.
INSTRUCTIONS AND ADDITIONAL INFORMATION TO CANDIDATES FOR RECRUITMENT BY SELECTION1. CITIZENSHIP :A Candidate must be either:(a) a citizen of India, or(b) a subject of Nepal, or(c) a subject of Bhutan, or
(d) a Tibetan refugee who came over to India before 1st January, 1962 with the intention of permanently settling in India, or
(e) a person of Indian origin who has migrated from Pakistan, Burma, Sri Lanka or East African countries of Kenya, Uganda, the United Republic of Tanzania(formerly Tanganyika and Zanzibar), Zambia, Malawi, Zaire, Ethiopia and Vietnam with the intention of permanently settling in India. Provided that a candidate belonging to categories (b), (c), (d) and (e) above shall be a person in whose favour a certificate of eligibility has been issued by the Government of India.
NOTE The application of a candidate in whose case a certificate of eligibility is necessary, may be considered by the Commission and, if recommended for appointment, the candidate may also be provisionally appointed subject to the necessary certificate being issued in his favour by the Government of India.
2. AGE LIMITS : The age limit for the post has been given in the advertisement. For certain age concessions admissible to various categories please go through the instruction regarding Concessions & Relaxations.
3. MINIMUM ESSENTIAL QUALIFICATIONS : All applicants must fulfill the essential requirements of the post and other conditions stipulated in the advertisement. They are advised to satisfy themselves before applying that they possess at least the essential qualifications laid down for various posts.
No enquiry asking for advice as to eligibility will be entertained. NOTE-I: The prescribed essential qualifications are the minimum and the mere possession of the same does not entitle candidates to be called for interview.
4. APPLICATION FEE :(a) Candidates are required to pay a fee of Rs. 25/- (Rupees Twenty five) only either by remitting the money in any branch of the SBI by cash or by using net banking facility of the SBI or by using visa/master credit/debit card.
(b) No fee for SC/ST/PwBD/Women candidates of any community. No "fee exemption" is available to Gen/OBC/EWS male candidates and they are required to pay the full prescribed fee.
(c) Applications without the prescribed fee would not be considered and summarily rejected. No representation against such rejection would be entertained.
(d) Fee once paid shall not be refunded under any circumstance nor can the fee be held in reserve for any other examination or selection.
1. Before filling up the Online Recruitment Application (ORA), the candidates must go through the detailed Advertisement available on the Commission's website.
Please proceed to fill the online application only if you are satisfied that you possess the minimum Essential Qualifications stipulated for the post in the detailed advertisement. Otherwise, submitted application(s) shall be outrightly rejected.
2. The date for determining the eligibility of all the candidates in every respect shall be the prescribed closing date for submission of Online Recruitment Application (ORA), unless specified otherwise.
3. The applicants are advised to fill in all their particulars in the Online Recruitment Application carefully as submission of wrong information may lead to rejection through computer based short-listing apart from debarment by the Commission.
4. The candidates are advised to fill their correct and active e-mail address in the online application as any Correspondence will be made by the Commission through e-mail only. The candidates are also advised to refer to website of the Commission for regular updates of the recruitment cases.
5. The applicants are advised to submit only single Online Recruitment Application for a particular post. However, if they submit multiple Online Recruitment Applications for one post, then they must ensure that the Online Recruitment Application with the higher 'Application Number' is complete in all respects including fee, wherever applicable.
The applicants, who submit multiple Online Recruitment Applications, should note that only the Online Recruitment Application with higher 'Application Number' shall be considered by the Commission and fee paid against one 'Application Number' shall not be adjusted against any other 'Application Number'.
6. Fee once paid shall not be refunded under any circumstance nor can the fee be held in reserve for any other examination or selection.
7. The candidates are not required to send the printouts of their online applications to the Commission. However, the Application will not be treated as finally submitted unless and until it is available under 'My Finally Submitted Application' Tab before the closing date and time.
Please retain a print out of your finally submitted online application (complete with Payment Details, if not fee-exempted applicant) as a proof of submission of your application to the Commission, whenever required.
8. All candidates whether in Government service or in Government owned industrial or other similar organizations or in private employment should submit their applications online directly to the Commission.
Persons already in Regular Government service, whether in permanent or temporary capacity other than casual/adhoc/daily wages/hourly paid/contract basis would be required to submit a declaration, whenever asked by the commission, that they had informed in writing to their Head of Office/Department while applying for this selection.
9. The candidates belonging to OBC (Creamy Layer), i.e., who have marked their Creamy Layer status as 'YES' in ORA are not entitled to reservation admissible to OBC candidates and they will be treated at par with "UNRESERVED (UR)" candidates.
Similarly, benefits of reservation to OBC/SC/ST category will be admissible only when post is reserved for them.
If post is not reserved for their respective category, they can apply against unreserved vacancy and in such case they will be treated at par with "UNRESERVED (UR)" candidates for all the purposes.10. The prescribed Essential Qualifications are the minimum and the mere possession of the same does not entitle candidates to be called for recruitment test/interview.
CLOSING DATE FOR SUBMISSION OF ONLINE RECRUITMENT APPLICATION (ORA) THROUGH ORA WEBSITE IS 23:59 HRS ON 31.03.2022
THE LAST DATE FOR PRINTING OF COMPLETELY SUBMITTED ONLINE APPLICATION IS UPTO 23:59 HRS ON01.04.2022
Apply Online
Govt Job: For Post of Scientists under Department of Science & Technology
Govt Job: For Pharma & Life Sciences candidates at NIF| Salary upto Rs. 54,000 pm
Govt Job: For Pharmacy professionals at NMPB – Pay upto 2 lakh per month
Govt Job: For Pharmacists under Staff Selection Board
Govt Job: For B.Pharm in FDA under Public Service Commission
Govt Job: For Doctoral Degree in Pharma at IMTech | Salary Rs. 42,000 pm
https://thehealthmaster.com/2022/03/27/govt-job-for-m-pharm-or-m-sc-at-upsc-salary-upto-rs-177500-pm-2/
UTI: यूरिनरी ट्रैक्ट इंफेक्शन में नजर आते हैं ये लक्षण: ऐसे करें Prevention
UTI: यूरिनरी ट्रैक्ट इंफेक्शन में नजर आते हैं ये लक्षण: ऐसे करें Prevention
https://thehealthmaster.com/?p=36313
Download office memorandum dt 25-03-2022, link given below.
New Delhi: In what can be termed as the highest price hike ever, the National Pharmaceutical Pricing Authority (NPPA), the apex price regulatory body has announced a price hike of 10.76607% for scheduled drugs-which are under price control vide its office memorandum dt 25-03-2022.
Download office memorandum dt 25-03-2022
Confirmation to this effect was recently given by the NPPA, Department of Pharmaceuticals, in its recently office memorandum.
The move comes the basis of Wholesale Price Index (WPI) data provided by the Office of the Economic Advisor, Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry whereby the annual change in the WPI works out as 10.76607% during the calendar year 2021 over the corresponding period in 2020.
Click for more articles on NPPA
National Pharmaceutical Pricing Authority (NPPA) under the aegis of the Department of Pharmaceuticals fixes the ceiling price of scheduled medicines as per provisions of the Drugs (Prices Control) Order, 2013.
NPPA has fixed ceiling prices of 886 scheduled formulations & 4 scheduled medical devices and fixed retail prices of 1,817 new drugs. The prices of these formulations are revised by the NPPA based on the WPI each year
In case of non-scheduled medicines, a manufacturer is at liberty to fix the Maximum Retail Price (MRP) launched by it, but is not allowed to increase the MRP of such formulations by more than 10% per annum.
The move will spell out costlier essential medicines for the people as majority of the essential drugs have their prices controlled by the government via their inclusion in the National List of Essential Medicines (NLEM).
NLEM lists drugs used to treat common conditions such as fever, infection, heart disease, hypertension, skin diseases and anaemia, among others.
Also read
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
Latest Notifications: EC Act (Essential Commodities Act)
FAQs – On DPCO: Drugs (Prices Control) Order, 2013
Maharashtra FDA to get 15 new Asstt. Commissioners to combat impending...
USFDA probe of Abbott facility finds quality control issues
DCGI calls on stakeholders to initiate Clinical Trials early
USFDA gives nod to Lupin for Sildenafil for oral suspension
NPPA’s expert panel recommends retail price for FDCs of anti-diabetic linagliptin
DCGI gives nod to Phase-3 Clinical Trial of Covovax Vaccine
Drug recall: This drug recalled due to detection of NDMA
Drug recall: Some lots of Blood Pressure Drug due to this…
CDSCO approves Sputnik Light vaccine for manufacture for sale in India
Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/03/27/nppa-allows-price-hike-of-essential-medicines-by-more-than-10-percent/
Download the Latest notifications - NPPA / DPCO | Drugs Price Control Order, National Pharmaceuticals Pricing Authority
Govt. of India issues Notifications time to time which are published by Department of Publication and are printed by the Government of India Printing Presses regularly.
We have provided some of the notifications relevant to the above said topic, Click below links for more information:
2022
OM.-dt-25-03-2022-Movement-in-Wholesale-Price-Index-WPI-for-the-preceding-calendar-year-2021
S.O.-796E-dt-18-02-2022-NPPA-has-fixed-ceiling-prices-of-19-formulations-under-Drugs-Prices-Control-Order-2013
2021
S.O.-401E-dt-31-01-2022-Extension-of-Trade-Margin-Rationalization-on-5-Medical-Devices-namely-Pulse-Oximeter-Blood-Pressure-Monitoring-Machine-Nebulizer-Digital-Thermometer-and-Glucometer
S.O.-5428E-dt-28-12-2021-Extension-Revised-ceiling-price-of-Dextrose-Injection-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O.-5427E-dt-28-12-2021-Extension-Revised-ceiling-price-of-Mannitol-Injection-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O.-5426E-dt-28-12-2021-Extension-Revised-ceiling-price-of-Metronidazole-Injection-IP-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O.-5425E-dt-28-12-2021-NPPA-has-fixed-ceiling-prices-of-2-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O.-5424E-dt-28-12-2021-Extension-of-price-of-Liquid-Medical-Oxygen-LMO-and-Oxygen-Inhalation-Medicinal-Gas-in-cylinder-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O.-5423E-dt-28-12-2021-NPPA-has-fixed-retail-prices-of-28-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-94th-Authority-meeting-dated-23.12.2021.
S.O.-4885E-dt-26-11-2021-NPPA-has-fixed-ceiling-prices-of-2-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-93rd-Authority-meeting-dated-15.11.2021.
S.O.-4884E-dt-26-11-2021-NPPA-has-fixed-retail-prices-of-47-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-93rd-Authority-meeting-dated-15.11.2021.
OM-dt-22-11-2021-on-Paragraph-28-of-DPCO-2013-regarding-refusal-to-sell-drugs-by-manufacturers
S.O.-4241E-dt-12-10-2021-Addendum-to-S.-O.-3934E-dated-23.09.2021-Methotrexate-Topical-Gel
NPPA-OM-dt-30-09-2021-increase-in-GST-rate-Medical-Devices
S.O.-3939E-dt-23-09-2021-Revised-ceiling-price-of-Dextrose-Injection-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O.-3938E-dt-23-09-2021-Revised-ceiling-price-of-Mannitol-Injection-20-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O.-3937E-dt-23-09-2021-Revised-ceiling-price-of-Metronidazole-Injection-IP-in-100ml-pack-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O.-3936E-dt-23-09-2021-Extension-of-price-of-Liquid-Medical-Oxygen-LMO-and-Oxygen-Inhalation-Medicinal-Gas-in-cylinder-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O.-3934E-dt-23-09-2021-NPPA-has-fixed-retail-prices-of-23-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O.-E-dt-23-09-2021-Extension-of-revised-ceiling-price-of-Heparin-Injection-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-92nd-Authority-meeting-dated-08.09.2021.
S.O-3783E-dt-15-09-2021-NPPA-has-revised-retail-prices-of-1-formulation-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-91st-Authority-meeting-dated-29.07.2021.
S.O.-3670E-dt-10-09-2021-Regarding-ceiling-price-fixation-or-revision-of-Orthopaedic-Knee-Implants-for-Knee-Replacement-System
S.O.-3400E-dt-19-08-2021-NPPA-has-fixed-retail-prices-of-19-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-91st-Authority-meeting-dated-29.07.2021
S.O.-3249E-dt-12-08-2021-Amendment-in-paragraph-18-of-DPCO-2013
S.O-3162E-dt-06-08-2021-NPPA-has-fixed-retail-prices-of-6-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-91st-Authority-meeting-dated-29.07.2021
NPPA-Office-Memorandum-03-08-2021-Submission-of-price-related-information-for-Knee-Implants
NPPA-Office-Memorandum-dt-23-07-2021-–-for-Revised-MRPs-in-pursuance-to-the-TMR-Notification-for-5-Medical-Devices
S.O.-2899E-dt-20-07-2021-Order-on-Amendment-in-the-Drugs-Prices-Control-Order-2013-for-inclusion-on-Form-VI
S.O.-2820E-dt-14-07-2021-NPPA-has-fixed-retail-prices-of-14-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-89th-Authority-meeting-dated-28.06.2021
NPPA-S.O.-2808-dt-13-07-2021-Trade-Margin-Rationalisation-TMR-of-5-Medical-Devices
S.O.-2742E-dt-08-07-2021-NPPA-has-fixed-retail-prices-of-11-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-89th-Authority-meeting-dated-28.06.2021
NPPA-Office-Memorandum-dt-05-07-2021-On-Ceiling-or-Retail-Price-for-Amphotericin-B-Emulsion-Injection-50mg.
S.O.-2654E-dt-01-07-2021-Revision-of-price-of-3-drugs-under-Para-19-of-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-89th-Authority-meeting-dated-28.06.2021.
S.O.-2653E-dt-01-07-2021-Exemption-to-Torrent-Pharmaceutical-for-Tapentadol-Nasal-Spray-under-Para-32-of-DPCO-2013-based-on-the-decision-of-89th-Authority-meeting-dated-28.06.2021
S.O-2334E-dt-15-06-2021-NPPA-has-fixed-retail-prices-of-3-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-87th-Authority-meeting-dated-25.05.2021.
NPPA-Dt-09-06-2021-Office-Memorandum-Revised-MRP-for-Oxygen-Concentrators
NPPA-Office-Memorandum-dt-04-06-2021-In-pursuance-to-the-Notification-dated-03.06.2021-for-Oxygen-Concentrators
NPPA-order-dt-03-06-2021-Price-Cap-for-Oxygen-Concentrator-through-Trade-Margin-Rationalisation-Approach
S.O-2119E-dt-01-06-2021-NPPA-has-fixed-retail-prices-of-12-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-87th-Authority-meeting-dated-27.05.2021.
NPPA-Office-Memorandum-dt-15-05-2021-for-call-of-MRP-Data-for-Pulse-Oximeter-Oxygen-Concentrator-2021
S.O.-1859-dt-14-05-2021-NPPA-has-fixed-retail-prices-of-2-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-86th-Authority-meeting-dated-28.04.2021
S.O.-1725-dt-30-04-2021-NPPA-has-fixed-ceiling-price-of-1-formulation-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-86th-Authority-meeting-dated-28.04.2021.
S.O.-1724-dt-30-04-2-21-NPPA-has-fixed-retail-prices-of-42-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-86th-Authority-meeting-dated-28.04.2021.
NPPA-Office-memorandum-dt-17-04-2021-List-of-Reduced-Prices-of-Remdesivir-of-7-companies
NPPA-12-04-2021-Remdesivir-Contact-Details-and-Helpline-Numbers-for-availability
S.O.-1335E-dt-25-03-2021-Prices-of-Liquid-Medical-Oxygen-and-Medicinal-gas-extended-upto-30-09-2021
S.O.-1334E-dt-25-03-2021-Revised-ceiling-prices-WPI-adjusted-for-two-2-Coronary-Stents.
S.O.-1333E-dt-25-03-2021-Revised-ceiling-prices-WPI-adjusted-of-4-pack-size-of-ringer-lactate-injection-with-packages-having-special-features.
S.O.-1332E-dt-25-03-2021-Revised-ceiling-prices-WPI-adjusted-of-8-IV-Fluids-with-packages-having-special-features.
S.O.-1331E-dt-25-03-2021-Revised-ceiling-price-WPI-adjusted-of-9-scheduled-formulations-of-Schedule-INLEM-2011-under-Drugs-Prices-Control-Order2013.
S.O.-1330E-dt-25-03-2021-Revised-ceiling-price-WPI-adjusted-of-866-scheduled-formulations-of-Schedule-I-under-Drugs-Prices-Control-Order-2013.
S.O.-1329E-dt-25-03-2021-NPPA-has-fixed-ceiling-price-of-1-formulation-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-84th-Authority-meeting-dated-10.03.2021.
S.O-1328E-dt-25-03-2021-NPPA-has-fixed-retail-prices-of-35-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-84th-Authority-meeting-dated-10.03.2021.
NPPA-Office-Memorandum-dt-18-03-2021-Movement-in-Wholesale-Price-Index-WPI-for-the-preceding-calendar-year-2020
S.O.-1238-dt-17-03-2021-Extension-of-S.O.-4539E-dated-18.12.2019-of-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-84th-Authority-meeting-dated-10.03.2021
S.O.-1237-dt-17-03-2021-Extension-of-S.O.-4538E-dated-18.12.2019-of-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-84th-Authority-meeting-dated-10.03.2021
S.O.-1236-dt-17-03-2021-Extension-of-revised-ceiling-price-of-Heparin-Injection-based-on-the-decision-of-84th-Authority-meeting-dated-10.03.2021
S.O.-1235-dt-17-03-2021-NPPA-has-fixed-retail-price-of-3-formulations-after-expiry-of-exemption-granted-under-para-32-of-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-84th-Authority-meeting-dated-10.03.2021
S.O.-1208-dt-15-03-2021-NPPA-has-fixed-retail-prices-of-41-formulations-under-Drugs-Prices-Control-Order-2013-based-on-the-decision-of-84th-Authority-meeting-dated-10.03.2021
NPPA-dt-12-03-2021-Monitoring-of-MRPs-for-Medical-Devices-dated-16.02.2021-with-Annexures
NPPA-dt-18-02-2021-Display-of-draft-version-of-proposed-price-calculation-sheet-for-24-proposed-retail-price-based-on-June-2020-Data-under-Para-4-of-DPCO-2013
NPPA-Office-Memorandum-dt-16-02-2021-on-Monitoring-of-MRPs-for-Medical-Devices-with-Annexures
S.-O.-575-E-dt-09-02-2021-NPPA-has-fixed-the-ceiling-prices-of-13-formulations-under-Drugs-Prices-Control-Order-2013
S.-O.-523-E-dt-04-02-2021-NPPA-has-fixed-the-ceiling-prices-of-8-formulations-under-Drugs-Prices-Control-Order-2013-relating-to-83rd-Authority-meeting-dated-27-01-2021
S.O.-508E-dt-01-02-2021-Amendment-in-Schedule-I-of-the-DPCO-2013
NPPA-Memorandum-dt-11-01-2021-Provisional-List-of-324-Over-Charging-cases-under-litigation
S.-O.-95-E-dt-08-01-2021-NPPA-has-fixed-the-ceiling-prices-of-12-formulations-under-Drugs-Prices-Control-Order-2013-relating-to-82nd-Authority-meeting-dated-23-12-2020
2020
S.-O.-4774-E-dt-31-12-2020-Price-exemption-of-FDC-of-Sun-Pharma-under-para-321-of-DPCO-2013-relating-to-82nd-Authority-meeting-dated-23-12-2020
S.-O.-4773-E-dt-31-12-2020-NPPA-has-fixed-the-ceiling-prices-of-7-formulations-under-Drugs-Prices-Control-Order-2013-relating-to-82nd-Authority-meeting-dated-23-12-2020
S. O. 4498(E) dt 11-12-2020 – NPPA has fixed the ceiling prices of 3 formulations under Drugs (Prices Control) Order, 2013 relating to 81th Authority meeting dated 24.11.2020
S.O-4333E-dt-03-12-2020-Extension-of-revised-price-of-Heparin-Injection-based-on-the-decision-of-81st-Authority-meeting-dated-24.11.2020
SO-3977-E-dt-03-11-2020-NPPA-has-fixed-the-ceiling-prices-of-2-formulations-under-Drugs-Prices-Control-Order-2013-relating-to-80th-Authority-meeting-dated-26.10.2020PDF-icon
SO-3976-E-dt-03-11-2020-NPPA-has-fixed-the-ceiling-prices-of-6-formulations-under-Drugs-Prices-Control-Order-2013-relating-to-80th-Authority-meeting-dated-26.10.2020
SO-3975-E-dt-03-11-2020-Addendum-to-SO.-1216-E-dated-25.03.2020-relating-to-80th-Authority-meeting-dated-26.10.2020
SO-3974-E-dt-03-11-2020-Addendum-to-SO.-1215-E-dated-25.03.2020-relating-to-80th-Authority-meeting-dated-26.10.2020
S.O.-3973E-dt.-03-11-2020-NPPA-has-fixed-retail-prices-of-29-formulations-under-Drugs-Prices-Control-Order-2013-relating-to-80th-Authority-meeting-dated-26-10-2020
S.O.-3322-E-dt-25-09-2020-Price-Cap-for-Medical-Liquid-Oxygen-and-Oxygen-Inhalation-Medicinal-gas-in-Cylinder
S.O.-3319-E-dt-25-09-2020-NPPA-has-fixed-retail-prices-of-26-formulations-under-Drugs-Prices-Control-Order-2013-relating-to-78th-Authority-meeting-dated-14.09.2020
Office-memorandum-dt-25-09-2020-–-Clarification-regarding-revision-of-Ceiling-Prices-of-Orthopaedic-Knee-Implants-for-the-year-2020
NPPA-order-dt-24-09-2020-for-submission-of-data-by-manufacturers-and-re-fillers-of-medical-oxygen
S.O.-3147E-15-09-2020-Notification-regarding-ceiling-price-fixation-revision-of-orthopedic-Knee-Implants-for-Knee-Replacement-System
S.O.-No.-2896-dt-27-08-2020-NPPA-has-fixed-retail-prices-of-1-formulation-under-Drugs-Prices-Control-Order-2013-relating-to-77th-Authority-meeting-dated-06.08.2020
S.O.-2822E-dt-20-08-2020-NPPA-has-fixed-retail-prices-of-29-formulations-under-Drugs-Prices-Control-Order-2013-relating-to-77th-Authority-meeting-dated-06.08.2020
NPPA-Office-memorandum-dt.-14-08-2020-Guidelines-for-Discontinuation-of-Scheduled-Formulation
S.O.-No.-2768-E-dated-14-08-2020-regarding-prices-of-Knee-implants-extended-upto-15-09-2020
S.O.-2293E-dt.-10-07-2020-NPPA-HAS-FIXED-RETAIL-PRICES-OF-7-FORMULATIONS-UNDER-DRUGS-PRICES-CONTROL-ORDER-2013-RELATING-TO-76TH-AUTHORITY-MEETING-DATED-22.06.2020
S.O.-2292E-dt.-10-07-2020-REVISION-OF-CEILING-PRICE-OF-1-FORMULATION-BASED-ON-REVIEW-ORDER-RELATING-TO-76TH-AUTHORITY-MEETING-DATED-22.06.2020
SO-2151E-dt-30-06-2020-Revised-ceiling-price-of-Heparin
S.O. 2150 dt. 30-06-2020 – NPPA has fixed retail prices of 14 formulations under Drugs (Prices Control) Order, 2013
NPPA-Office-Memorandum-dt-03-06-2020-regarding-revised-MRPs-of-N-95-masks
NPPA-dt-01-06-2020-Draft-guidelines-for-dealing-cases-of-discontinuation-of-scheduled-formulations-under-Para-21-2-of-DPCO 2013.
S.O.-1674 (E) 28-05-2020 NPPA has fixed revised retail prices of 40 formulation under Drugs (Prices Control) Order, 2013
S.O-No.-1232-E-dt-31-03-2020-All-Medical-devices-under-DPCO
NPPA-Order-dated-25.03.2020-to-maintain-stock-of-Lopinavir-Ritonavir-Tablets
S.O.-1217-dt-25-03-2020-NPPA-has-fixed-revised-retail-prices-of-2-items-Stents-under-Drugs-Prices-Control-Order-2013
S.O.-1216-dt-25-03-2020-16-items-Ringer-Lactate-Price-revision-as-per-annual-wholesale-price-Index-WPI-@-1.88468-increase
S.O.-1215-dt-25-03-2020-8-items-Glucose-Sod-Chloride-etc.-Price-revision-as-per-annual-wholesale-price-Index-WPI-@-1.88468-increase
S.O.-1214-dt-25-03-2020-13-items-Salicylic-acid-Cal-carbonate-Condom-etc.-Price-revision-as-per-annual-wholesale-price-Index-WPI-@-1.88468-increase
S.O.-1213-dt-25-03-2020-856-items-Price-revision-as-per-annual-wholesale-price-Index-WPI-@-1.88468-increase
S.O.-07-02-2020-NPPA-has-fixed-retail-prices-of-21-formulations-under-Drugs-Prices-Control-Order-2013
S.O.-28-01-2020-NPPA-has-fixed-retail-prices-of-17-formulations-under-Drugs-Prices-Control-Order-2013
2019
S.O.-31-12-2019-NPPA-has-fixed-retail-prices-of-7-formulations-under-Drugs-Prices-Control-Order-2013
S.O.-18-12-19-NPPA-has-fixed-revised-retail-prices-of-Digital-dose-counter-Glenmark-under-Drugs-Prices-Control-Order-2013
S.O.-13-12-2019-NPPA-has-fixed-revised-retail-prices-of-21-formulation-under-Drugs-Prices-Control-Order-2013
S.O.-14-11-2019-NPPA-has-fixed-revised-retail-prices-of-12-formulation-under-Drugs-Prices-Control-Order-2013
S.O.-4063-E-08-11-2019-NPPA-has-fixed-revised-retail-prices-of-14-formulation-under-Drugs-Prices-Control-Order-2013
S.O.-4062-E-08-11-2019-NPPA-has-fixed-revised-retail-prices-of-59-formulation-under-Drugs-Prices-Control-Order-2013
S.O.-4061-E-08-11-2019-NPPA-has-fixed-revised-retail-prices-of-1-formulation-under-Drugs-Prices-Control-Order-2013
S.O.-4060-E-08-11-2019-NPPA-has-fixed-revised-retail-prices-of-1-formulation-under-Drugs-Prices-Control-Order-2013
S.O.-39E-dt-03-01-2019-Amendment-of-Paragraph-9-and-32-of-DPCO-2013
2016
S.O.1192E-dt-22-03-2016-Amendment-of-Paragraph-11-of-DPCO-2013
S.O.-701E-dt-10-03-2016-Drugs-Price-Control-Amendment-Order-2016-Regarding-Schedule-I-Drugs-and-dosage-form
2015
S.O.-686E-dt-09-03-2015-Amendments-in-Drugs-Prices-Control-Order-2013
For more Notifications on following topics, click below links:
Banned Drugs
Blood Bank / Centre
Cosmetics
COTPA
Drug Rules
Drugs Act
DMROA
EC Act
General
Homoeopathic
Hospital – RMI
Medical Devices
NDPS Act
New Drugs
Testing Laboratories
https://thehealthmaster.com/2021/02/14/latest-notifications-nppa-dpco/
Subscribe to:
Posts (Atom)